Thrombosis Research
Volume 126, Issue 2 , Pages 93-97 , August 2010

Prophylactic therapy with enoxaparin in children with acute lymphoblastic leukemia and inherited thrombophilia during L-asparaginase treatment

  • Dan Harlev

      Affiliations

    • Department of Pediatric Hematology Oncology, Meyer Children's Hospital, Rambam Health Care Campus, Haifa, Israel
    • ,
  • Irina Zaidman

      Affiliations

    • Department of Pediatric Hematology Oncology, Meyer Children's Hospital, Rambam Health Care Campus, Haifa, Israel
    • ,
  • Galit Sarig

      Affiliations

    • Hematology Laboratory, Rambam Health Care Campus, Haifa, Israel
    • ,
  • Myriam Weyl Ben Arush

      Affiliations

    • Department of Pediatric Hematology Oncology, Meyer Children's Hospital, Rambam Health Care Campus, Haifa, Israel
    • Thrombosis and Hemostasis Unit and Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel
    • ,
  • Benjamin Brenner

      Affiliations

    • Thrombosis and Hemostasis Unit and Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel
    • B. Rappaport Faculty of Medicine, Technion-Institute of Technology, Haifa, Israel
    • ,
  • Ronit Elhasid

      Affiliations

    • Department of Pediatric Hematology Oncology, Meyer Children's Hospital, Rambam Health Care Campus, Haifa, Israel
    • Thrombosis and Hemostasis Unit and Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel
    • Corresponding Author InformationCorresponding author. Department of Pediatric Hematology Oncology, Meyer Children's Hospital, Rambam Health Care Campus, 8 Ha'Aliyah Street, Haifa 35254, Israel. Tel.: +972 4 8542062; fax: +972 4 8542007.

Received 16 May 2009 ,Revised 7 April 2010 ,Accepted 22 April 2010.

References 

  1. Mitchell L, Hoogendoorn H, Giles AR, Vegh P, Andrew M. Increased endogenous thrombin generation in children with ALL: risk of thrombotic complications in L-asparginase induced antithrombin III deficiency. Blood. 1994;83:386–391
  2. Sameroro N, Montemurro P, Giordano PW, Schettini F, Santoro N, De Mattia D, et al. Unbalanced coagulation-fibrinolysis potential during L-asparginase therapy in children with acute lymphoblastic leukemia. Thromb Haemost. 1990;64:38–40
  3. Clavell LA, Gelber RD, Cohen HJ, Hitchcock-Bryan S, Cassady JR, Tarbell NJ, et al. Four agent induction and intensive asparginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med. 1986;315:657–663
  4. Priest JR, Ramsay NKC, Steinherz PG, Tubergen DG, Cairo MS, Sitarz AL, et al. A syndrome of thrombosis and hemorrhage complicating L-asparginase therapy for childhood acute lymphoblastic leukemia. J Pediatr. 1982;100:984–989
  5. Gugliotta L, Mazzucconi MG, Leone G, Mattioli-Belmonte M, Defazio D, Annino L, et al. Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L-asparaginase during induction therapy: a retrospective study. Eur J Haematol. 1992;49:63–66
  6. Shapiro AD, Clarke SL, Christian JM, Odom LF, Hathaway WE. Thrombosis in children receiving L-asparginase. Determining patients at risk. Am J Pediatr Hematol Oncol. 1993;15:400–405
  7. Korte W, Feldges A, Baumgartner C, Ullmann S, Niederer V, Schmid L. Increased thrombin generation during fibrinogen and platelet recovery as an explanation for hypercoagulability in children with L-asparaginase therapy for ALL or NHL: a preliminary report. Klin Padiatr. 1994;206:331–333
  8. Mitchell L, Hoogendoorn H, Giles AR, Vegh P, Andrew M. Increased endogenous thrombin generation in children with ALL: risk of thrombotic complications in L-asparaginase induced antithrombin III deficiency. Blood. 1994;83:386–391
  9. Mitchell LG, Andrew M, Hanna K, Abshire T, Halton J, Anderson R, et al. A prospective cohort study determining the prevalence of thrombotic events in children with ALL and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with ALL Treated with Asparaginase (PARKAA) study. Cancer. 2003;97:508–516
  10. Sutor AH, Mall V, Thomas KB. Bleeding and thrombosis in children with ALL treated according to the BFM-90 protocol. Klin Padiatr. 1999;211:201–204
  11. Wermes C, von Depka Prondzinski M, Lichtinghagen R, Barthels M, Welte K, Sykora KW. Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters. Eur J Pediatr. 1999;158(suppl. 3):S143–S146
  12. Mauz-Korholz C, Junker R, Gobel U, Nowak-Gottl U. Prothrombotic risk factors in children with ALL treated with delayed E.coli asparaginase (COALL-92 and 97 protocols). Thromb Haemost. 2000;83:840–843
  13. Nowak-Gottl U, Hainecke A, von Kries R, Nürnberger W, Münchow N, Junker R. thrombotic events revisited in children with ALL: impact of concomitant e.coli asparaginase/prednisone administration. Thromb Res. 2001;103:165–172
  14. Nowak-Gottl U, Ahlke E, Fleischhack G, Schwabe D, Schobess R, Schumann C, et al. Thromboembolic events in children with ALL (BFM protocols): prednisone versus dexamethasone administration. Blood. 2003;101:2529–2533
  15. Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, et al. Improved outcome for children with ALL: results of Dana-Farber consortium protocol 91-01. Blood. 2001;97:1211–1218
  16. Athale UH, Chan AKC. Thrombosis in children with ALL: epidemiology of thrombosis in children with ALL. Thromb Res. 2003;111:125–131
  17. Caruso V, Iacoviello L, Di Castelnuovo A, Storti S, Mariani G, de Gaetano G, et al. Thrombotic complications in childhood ALL: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood. 2006;108:2216–2222
  18. Athale UH, Chan AKC. Thrombosis in children with ALL: pathogenesis of thrombosis in children with ALL: effect of the disease and therapy. Thromb Res. 2003;111:199–212
  19. Athale UH, Chan AKC. Thrombosis in children with ALL: pathogenesis of thrombosis in children with ALL: effect of host environment. Thromb Res. 2003;111:321–327
  20. Jaime-Perez JC, Gomez-Almaguer D. The complex nature of the prothrombotic state in ALL of childhood. Haematologica. 2003;88:ELT25
  21. Payne JH, Vora AJ. Thrombosis and acute lymphoblastic leukaemia. Br J Haematol. 2007;138:430–445
  22. Bushman JE, Palmieri D, Whinna HC, Church FC. Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood ALL. Leuk Res. 2000;24:559–565
  23. Mitchell LG, Sutor AH, Andrew M. Hemostasis in childhood ALL: coagulopathy induced by disease and treatment. Semin Thromb Hemost. 1995;21:390–401
  24. Korones DN, Buzzard CJ, Asselin BL, Harris JP. Right atrial thrombi in children with cancer and indwelling catheters. J Pediatr. 1996;128:841–846
  25. Male C, Chait P, Andrew M, Hanna K, Julian J, Mitchell L, et al. Central venous line-related thrombosis in children: association with central venous line location and insertion technique. Blood. 2003;101:4273–4278
  26. Nowak-Gottl U, Wermes C, Junker R, Koch HG, Schobess R, Fleischhack G, et al. Prospective evaluation of the thrombotic risk in children with ALL carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant and further prothrombotic risk factors. Blood. 1999;93:1595–1599
  27. Elhasid R, Lanir N, Sharon R, Weyl Ben Arush M, Levin C, Postovsky S, et al. Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with ALL. Blood Coagul Fibrinolysis. 2001;12:367–370
  28. Dix D, Andrew M, Marzinotto V, Charpentier K, Bridge S, Monagle P, et al. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr. 2000;136:439–445
  29. Ruud E, Holmstrom H, De Lange C, Hogstad EM, Wesenberg F. Low-dose warfarin for the prevention of central line associated thromboses in children with malignancies- a randomized controlled study. Acta Paediatr. 2006;95:1053–1059
  30. Couban S, Goodyear M, Burnell M, Dolan S, Wasi P, Barnes D, et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol. 2005;23:4063–4069
  31. Verso M, Agnelli G, Bertoglio S, Di Somma FC, Paoletti F, Ageno W, et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double blind, placebo controlled, randomized study in cancer patients. J Clin Oncol. 2005;23:4057–4062
  32. Mauz-Korholz C, Junker R, Gobel U, Nowak-Gottl U. Protrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols). Thromb Haemost. 2000;83:840–843
  33. Nowak-Gottl U, Kenet G, Mitchell L. Thrombosis in childhood acute lymphoblastic leukemia: epidemiology, aetiology, diagnosis, prevention and treatment. Best Pract Res Clin Haematol. 2009;22:103–114
  34. Brenner B, Sarig G, Weiner Z, Yunis J, Blumenfeld Z, Lanir N. Thrombophilic polymorphism are common in women with fetal loss without apparent cause. Thromb Haemost. 1999;82:6–9
  35. Young G, Becker S, During C, Friedrichs F, Goldenberg N, Kenet G, et al. Influence of the factor II G20210A variant or the factor V G1691A mutation on symptomatic recurrent venous thromboembolism in children: an international multicenter cohort study. J Thromb Haemost. 2009;7:72–79
  36. Athale U, Siciliano SA, Crowther M, Barr RD, Chan AKC. Thromboembolism in children with acute lymphoblastic leukemia treated on Dana-Farber Cancer institute protocols: effect of age and risk stratification of disease. British J of Haematology. 2005;129:803–810
  37. Meister B, Kropshofer G, Klein-Franke A, Strasak AM, Hager J, Streif W. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;50:298–303
  38. Mitchell L, Lambers M, Flege S, Kenet G, Li-Thiao-Te V, Holzhauer S, et al. Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia:results of a multicenter cohort study. Blood. 2010 Apr 7;[Epub ahead of print]

PII: S0049-3848(10)00251-3

doi: 10.1016/j.thromres.2010.04.013

Thrombosis Research
Volume 126, Issue 2 , Pages 93-97 , August 2010

Article Tools